Qlucore (QCORE) Q1 26/27 earnings summary

Executive summary

• Net sales for the first quarter rose 110% year-over-year to SEK 1,704k, driven by a new industrial customer and a delayed renewal from an existing customer.

• Adjusted EBITDA improved to SEK -2,095k from SEK -5,385k year-over-year, reflecting significant cost savings.

• Net result for the period was SEK -2,862k, a marked improvement from SEK -6,619k in the prior year.

• Cash flow from operating activities increased to SEK 4,089k, and net cash flow reached SEK 3,070k.

• A strategic reseller agreement with BioTuring was signed, expanding the product portfolio and market reach.

Financial highlights

• Net sales: SEK 1,704k (up from SEK 811k year-over-year).

• Adjusted EBITDA: SEK -2,095k (improved from SEK -5,385k year-over-year).

• Operating result (EBIT): SEK -2,829k (up from SEK -6,552k year-over-year).

• Net result: SEK -2,862k (up from SEK -6,619k year-over-year).

• Cash and cash equivalents at period end: SEK 6,057k.

Outlook and guidance

• No formal market outlook or earnings forecast provided.

• Management expects the BioTuring partnership to broaden the customer base and increase revenue per customer.

• Ongoing development and planned launches for diagnostic products in lung, bladder, and AML cancers.